Latest news with #Viz.ai
Yahoo
13-06-2025
- Business
- Yahoo
FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module
The US Food and Drug Administration (FDA) has granted 510(k) clearance to for its Viz Subdural Plus module, designed for enhancing clinical decision-making. It is claimed to be the first solution to quantify the size of collections such as subdural haemorrhages (SDH) in the subdural space on non-contrast computed tomography images. This solution automatically labels subdural collections and reports measurements such as thickness, midline shift, and volume. According to the company, chronic subdural haematoma is anticipated to become the most prevalent cranial neurosurgical condition in the adult population by 2030 in the US, with an estimated 60,000 new cases each year. The precise assessment of subdural collections is crucial for assessing severity, tracking progression, and guiding timely interventions, particularly for those under consideration for MMA [middle meningeal artery] embolisation. The software solution is designed to streamline the analysis of subdural collections by automating a process that has traditionally been manual and laborious. Integrated into the One platform, the software is currently in use in 1,800 health systems and hospitals. The platform enhances disease detection, supports critical care decisions, and optimises care pathways to improve patient outcomes. product management senior director Justin Ryea said: 'With an ageing population, the incidence of chronic subdural hematomas is rising, and so is the need for intelligent, automated tools to assess volume when deciding on the appropriate intervention such as MMA embolisation. 'Viz Subdural Plus, along with intracerebral haemorrhage measurements, exemplify how we're expanding our capabilities in our market-leading Viz Neuro Suite to address high-impact conditions, reduce variability in care, and drive better outcomes at scale.' The company leverages AI algorithms and machine learning to expedite diagnosis and care in the US and European healthcare systems. Last year, disclosed new trial data evaluating its AI-powered neurovascular technology that can detect and diagnose various neurological pathologies, including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA), and brain haemorrhage. "FDA grants 510(k) clearance to Viz Subdural Plus module" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module
The US Food and Drug Administration (FDA) has granted 510(k) clearance to for its Viz Subdural Plus module, designed for enhancing clinical decision-making. It is claimed to be the first solution to quantify the size of collections such as subdural haemorrhages (SDH) in the subdural space on non-contrast computed tomography images. This solution automatically labels subdural collections and reports measurements such as thickness, midline shift, and volume. According to the company, chronic subdural haematoma is anticipated to become the most prevalent cranial neurosurgical condition in the adult population by 2030 in the US, with an estimated 60,000 new cases each year. The precise assessment of subdural collections is crucial for assessing severity, tracking progression, and guiding timely interventions, particularly for those under consideration for MMA [middle meningeal artery] embolisation. The software solution is designed to streamline the analysis of subdural collections by automating a process that has traditionally been manual and laborious. Integrated into the One platform, the software is currently in use in 1,800 health systems and hospitals. The platform enhances disease detection, supports critical care decisions, and optimises care pathways to improve patient outcomes. product management senior director Justin Ryea said: 'With an ageing population, the incidence of chronic subdural hematomas is rising, and so is the need for intelligent, automated tools to assess volume when deciding on the appropriate intervention such as MMA embolisation. 'Viz Subdural Plus, along with intracerebral haemorrhage measurements, exemplify how we're expanding our capabilities in our market-leading Viz Neuro Suite to address high-impact conditions, reduce variability in care, and drive better outcomes at scale.' The company leverages AI algorithms and machine learning to expedite diagnosis and care in the US and European healthcare systems. Last year, disclosed new trial data evaluating its AI-powered neurovascular technology that can detect and diagnose various neurological pathologies, including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA), and brain haemorrhage. "FDA grants 510(k) clearance to Viz Subdural Plus module" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
09-06-2025
- Health
- Yahoo
New Study Demonstrates AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes in Intracerebral Hemorrhage Patients
Real-world data highlights how accelerates access to ICH treatment SAN FRANCISCO, June 09, 2025--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data showcasing the impact of Viz ICH and Viz ICH Plus in optimizing care for patients with intracerebral hemorrhage (ICH). The study, "Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology," highlights how AI-powered detection and quantification significantly reduced interhospital transfer (IHT) time, expediting treatment and improving patient outcomes. The case study features a 47-year-old patient with a right parieto-occipital hematoma who was rapidly identified by and transferred through the Neuroemergencies Management and Transfer (NEMAT) program. The use of Viz ICH and Viz ICH Plus cut the interhospital transfer time nearly in half - from an average of 200 minutes to just 101 minutes in this case - allowing the patient to undergo successful surgical evacuation and experience significant neurological recovery over the following year. "Viz ICH has transformed how we identify and triage patients with ICH," said Christopher Kellner, MD, Director of the Intracerebral Hemorrhage Program at Mount Sinai. "By accelerating diagnosis and enabling real-time alerts across teams and hospitals, this technology streamlines the entire transfer process, ensuring patients get the care they need without unnecessary delays." Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, requiring rapid diagnosis and intervention. Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and guiding treatment decisions. However, these measurements have traditionally been manual and time consuming. Radiologists, neurologists and neurosurgeons can incorporate Viz ICH and Viz ICH Plus seamlessly into their workflows to automate this process and support faster, more efficient care decisions. In addition to reducing transfer time, AI-powered detection and quantification has demonstrated improved efficiency in clinical workflows, with faster hematoma volume estimation and more accurate assessments compared to manual methods. The study also highlights the scalability of the solution across large, complex hospital systems where specialized ICH care may only be available at select sites. "At we are committed to using AI to close the gaps in stroke care and bring faster, more accurate treatment to every patient—no matter where they first present," said Molly Madziva Taitt, Ph.D., VP of Global Clinical Affairs at "This study is a powerful example of how AI can reduce delays, support earlier interventions, and ultimately improve outcomes for patients with intracerebral hemorrhage." To learn more about Viz ICH Plus, visit About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit View source version on Contacts Media Contacts Carolyn Daniel Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
09-06-2025
- Health
- Business Wire
New Study Demonstrates AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes in Intracerebral Hemorrhage Patients
SAN FRANCISCO--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data showcasing the impact of Viz ICH and Viz ICH Plus in optimizing care for patients with intracerebral hemorrhage (ICH). The study, ' Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology,' highlights how AI-powered detection and quantification significantly reduced interhospital transfer (IHT) time, expediting treatment and improving patient outcomes. The case study features a 47-year-old patient with a right parieto-occipital hematoma who was rapidly identified by and transferred through the Neuroemergencies Management and Transfer (NEMAT) program. The use of Viz ICH and Viz ICH Plus cut the interhospital transfer time nearly in half - from an average of 200 minutes to just 101 minutes in this case - allowing the patient to undergo successful surgical evacuation and experience significant neurological recovery over the following year. 'Viz ICH has transformed how we identify and triage patients with ICH,' said Christopher Kellner, MD, Director of the Intracerebral Hemorrhage Program at Mount Sinai. 'By accelerating diagnosis and enabling real-time alerts across teams and hospitals, this technology streamlines the entire transfer process, ensuring patients get the care they need without unnecessary delays.' Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, requiring rapid diagnosis and intervention. Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and guiding treatment decisions. However, these measurements have traditionally been manual and time consuming. Radiologists, neurologists and neurosurgeons can incorporate Viz ICH and Viz ICH Plus seamlessly into their workflows to automate this process and support faster, more efficient care decisions. In addition to reducing transfer time, AI-powered detection and quantification has demonstrated improved efficiency in clinical workflows, with faster hematoma volume estimation and more accurate assessments compared to manual methods. The study also highlights the scalability of the solution across large, complex hospital systems where specialized ICH care may only be available at select sites. 'At we are committed to using AI to close the gaps in stroke care and bring faster, more accurate treatment to every patient—no matter where they first present,' said Molly Madziva Taitt, Ph.D., VP of Global Clinical Affairs at 'This study is a powerful example of how AI can reduce delays, support earlier interventions, and ultimately improve outcomes for patients with intracerebral hemorrhage.' To learn more about Viz ICH Plus, visit About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit
Business Wire
02-06-2025
- Business
- Business Wire
Viz.ai Launches New Strategic Alliance to Accelerate Timely Diagnosis and Deliver AI-Powered Precision Care for Patients with Cancer
SAN FRANCISCO--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new multi-year collaboration with Novartis aimed at transforming cancer care through the development of proprietary AI-powered workflows within the Viz Oncology Suite. This strategic alliance will focus on improving the identification and stratification of patients diagnosed with prostate and breast cancers based on key risk factors, accelerating access to guideline-based precision treatments. For patients with cancer, every day matters. Yet too often, diagnosis and treatment are delayed by fragmented systems, manual reviews, and complex care journeys. These inefficiencies can lead to missed diagnoses, delayed access to life-extending therapies, and worse outcomes. This collaboration aims to address that, using AI to help ensure patients are surfaced and treated earlier, with care that's timely, coordinated, and personalized. 'We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer,' said Chris Mansi, MD, CEO and co-founder of 'This collaboration is part of our broader strategic expansion into oncology, furthering mission to fundamentally transform healthcare through intelligent care coordination.' As part of the collaboration will be developing two new AI-powered solutions: Viz Prostate Cancer, designed to streamline the identification of eligible patients for guideline-based treatment and support timely referrals to an appropriate specialist. Only one in four patients receives guideline-recommended therapy for prostate cancer, and thousands of patients with advanced disease who are eligible for potential life-extending treatments are never identified. 1,2 Viz Breast Cancer, designed to support breast oncologists by automating patient review, aggregating risk-relevant data, surfacing therapeutic guidelines, and facilitating coordination among multidisciplinary care teams. Breast cancer is the most widely diagnosed cancer in the United States, with patient care journeys that are complex, time-consuming, and often fragmented. 3 'Earlier diagnosis and interventions can positively impact patient outcomes. At Novartis, we lead the industry in fostering bold partnerships and initiatives that support early screening and diagnosis; we are also leveraging innovative, data-driven technologies to help connect patients with appropriate care as quickly as possible," said Rodney Gillespie, Head of Oncology, Novartis US. "By sharing key insights with we will develop AI-powered solutions to quickly help reach patients who could benefit from guideline-based targeted treatments for prostate and breast cancer, helping significantly expedite their care.' 'Too often, patients with cancer are identified late or fall through the cracks of an increasingly complex care system,' said Ethan M. Basch, MD, Chief of Oncology and Cancer Hospital Physician-in-Chief at UNC. 'AI-powered tools bring the potential to optimize how we detect, triage, and treat cancer—by delivering the right care, to the right patient, at the right time.' With this collaboration and expansion into oncology, is building on its commitment to create a connected, intelligent healthcare AI layer that delivers better care for every patient, everywhere. Learn more about Viz Oncology by visiting About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit References Goebell PJ, Raina R, Chen SL, et al. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol. 2024;20(11):903-918. doi:10.2217/fon-2023-0814 Reynolds S. Many men with metastatic prostate cancer are not getting the recommended treatments, study finds. Cancer Currents Blog. February 18, 2025. Accessed April 21, 2025. American Cancer Society. How common is breast cancer? American Cancer Society. Accessed April 21, 2025.
